key: cord-0799433-gztsz2vp
authors: Zheng, Guilang; Wang, Bangqin; Zhang, Hua; Xie, Chuxing; Zhang, Yuehua; Wen, Zhihong; Guo, Qingyun; Zhu, Hong; Ye, Guojing; Liang, Jiayi; Meng, Qiong; Xie, Jingquan; Jiang, Suhua; Liu, Guojun; Gao, Wenjun; Wang, Yanhao; Guo, Yuxiong
title: Clinical characteristics of acute respiratory syndrome with SARS‐CoV‐2 infection in children in South China
date: 2020-07-03
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.24921
sha: f4a64fd960f4367f46b81c71a50686518a110da8
doc_id: 799433
cord_uid: gztsz2vp

BACKGROUND: A retrospective study was conducted to summarize the clinical information of childhood infections during the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) epidemic. METHODS: Children with SARS‐CoV‐2 infection in 11 hospitals from three provinces of South China were included in the study. Clinical information was collected and compared with children and adults infected by SARS‐CoV‐2 in Wuhan. RESULTS: In total, 52 children were enrolled, including 28 boys. The median age was 9 years (interquartile range [IQR], 4‐12); 44.2% cases were of clustered occurrences, 40.4% patients had fever, 48.1% had cough, and 46.2% had a high lymphocyte count. No abnormalities were found in the liver and kidney function. Also, 82.7% of patients received antiviral therapy, but such therapy did not shorten the time to virus negativity or hospital stay (P = .082). The time to virus negativity was 12.0 days (IQR, 8.0‐16.8) and hospital stay was 14.5 days (IQR, 10.3‐17.9). Compared with reports in Wuhan, there were more acute upper respiratory tract infection (AURTI) and fewer pneumonia cases (P = .000). Compared with the non‐ICU adult COVID‐19 in Wuhan, these children's diseases were relatively mild, with fewer complications. CONCLUSIONS: Children with SARS‐CoV‐2 infection had a mild fever, lymphocyte elevation was more common than reduction, and antiviral treatment had no obvious effect. The overall clinical manifestations were mild, and the prognosis was good.

New coronavirus disease cases caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have increased significantly since the end of 2019, quickly spreading to more than 200 countries and regions 1, 2 and resulting in more than 8 000 000 COVID-19 infections, with the death toll surpassing 400 000. SARS-CoV-2 is mainly transmitted through respiratory droplets and contact. The whole population is susceptible, and the disease has the characteristics of human-to-human transmission and family clustering. 3, 4 The clinical manifestations of infected patients are mainly fever, cough, and body aches. In severe cases, shortness of breath and cyanosis may occur. Severe symptoms such as respiratory failure, acute respiratory distress syndrome (ARDS), and shock can be life-threatening. [5] [6] [7] [8] Epidemiologic data have shown that children with SARS-CoV-2 infection have been relatively few as compared with adults so far, [9] [10] [11] but pediatric infections have been reported from newborns through 18 year olds. [12] [13] [14] [15] There have been few reports on clinical features and systematic summaries of diagnosis and treatment in children. Therefore, in this study, we collected the epidemiological characteristics, clinical data, diagnosis, therapeutic process, and prognosis in pediatric patients with SARS-CoV-2 admitted to 11 hospitals in the three southern provinces of China before the world epidemic. We conducted a retrospective analysis and compared these data with the reported cases of infection in the representative province of Wuhan. 

The clinical data of children were collected from 11 hospitals in three provinces of South China retrospectively. Unified data collection forms were distributed to the researchers of the collaborating institutes, and they investigated and filled out the patients' medical records. The information was collected and summarized by Guangdong Province People's Hospital for statistical processing. The clinical data consisted of age, sex, weight, epidemiological investigation data, clinical symptoms and signs, laboratory and imaging examination data, main plans for diagnosis and treatment, and prognosis. The SARS-CoV-2 test was performed by sending the oropharyngeal swab specimen to the local Center for Disease Control for reversetranscription polymerase chain reaction (RT-PCR) to detect the SARS-CoV-2 nucleic acid. The data used in this study was anonymized before its use. This study protocol was reviewed and approved by the Medical Research Ethics Committee (No. The differences in sex composition, clinical classification of the disease, time to virus negativity, and length of hospital stay were analyzed.

This study was a multicenter retrospective study. Categorical variables are described as frequency rates and percentages, and continuous variables are described as mean, median, and interquartile range (IQR) values. Means for continuous variables were compared using one-way analysis of variance when the data were normally distributed; otherwise, the Kruskal-Wallis H test was used. Proportions for categorical variables were compared using the χ 2 test; however, Fisher's exact test was used when there were few data. The one-sample Wilcoxon signed rank test was used while comparing our patients with COVID-19 adults in Wuhan. All statistical analyses were done using SPSS (Statistical Package for the Social Sciences) version 19.0 software (SPSS Inc). For unadjusted comparisons, a twosided α < .05 value was considered statistically significant. 

There were 21 (40.4%) cases of fever that lasted from 1 to 4 days, mainly moderate to low fever (<38.3°C). There were 25 (48.1%) patients with cough, 5 (9.6%) with systemic fatigue and soreness, 3 (9.6%) with sore throat, and 1 (1.9%) with gastrointestinal symptoms.

No shortness of breath, cyanosis, or shock were reported in these patients; also, 13 patients were completely asymptomatic (23.1%).

According to the classification of the children's SARS-CoV-2 infection consensus, 6 28.7% of patients suffered from shortness of breath, which was significantly different from our study (no shortness of breath). This suggests that pediatric infection of SARS-CoV-2 in the Wuhan area was relatively more severe than in the children in this study. In Wuhan, 98% of non-ICU adult inpatients with COVID-19 5 had fever and 30.4% of the patients had experienced shortness of breath, which were significantly different from the rates in our sample; however, the proportions with symptoms of cough and headache were similar.

In the auxiliary tests, 6 (11.5%) patients had low leukocyte counts in the first blood routine at admission, and the median leukocyte count was 6.6 × 10 9 /L (IQR, 4.7-8.4). The lymphocyte count was high in 24 (46.2%) cases and low in 6 (11.5%) cases. The median lymphocyte count was 2.4 × 10 9 /L (IQR, 1.8-4.3). The procalcitonin level in 28 (68.3%) patients was higher than 0.05 ng/mL, but it was less than 1 ng/mL in all patients. Other routine tests showed no abnormalities (Table 1) . Among the reported non-ICU adult COVID-19 patients in Wuhan, the median leukocyte count was 4.3 × 10 9 /L (IQR, 3.3-5.4) and the median lymphocyte count was 0.9 × 10 9 /L (IQR, 0.6-1.2), which were significantly different from those in the pediatric COVID-19 patients in this study ( Table 1) .008

Lym, ×109/L which is similar to those in children with common viral infections.

SARS-CoV-2 may result in severe and critical cases, perhaps due to excessively activated inflammatory reaction 21, 22 and immune dysfunction. 23 In our study, however, the overall condition was mild, without respiratory complications, ARDS, AKI, or shock complications, and there were no severe or critical cases. Compared with children with SARS-CoV-2 infection in Wuhan, the clinical manifestations were similar, but the overall condition was milder. 9,20 Similar to milder cases of adult COVID-19, no myocardial, liver, or coagulation dysfunction was apparent in children with mild pneumonia.

Some drugs have been found to be possibly effective for the novel coronavirus pneumonia, 24 but there is neither enough evidence nor a specific drug for clinical treatment of COVID-19. The treatment is mainly isolation and symptomatic and supportive therapies. 10, 25 Ribavirin, arbidol, lopinavir/ritonavir, and recombinant human interferon-alpha 6 are possible anti-SARS-CoV-2 drugs that have been tried during severe epidemics. 5, 26 In this study, 82.7% of patients were administered one or more of these drugs; 42.3% received monotherapy and 40.4% received multiple drugs. The use of antiviral drugs had no significant effect on shortening the length of hospitalization or shortening the time to virus negativity. In contrast, the results suggested that there was a trend toward a longer time for SARS-CoV-2 to turn negative in the patients treated by two or more antiviral drugs, suggesting that antiviral treatment is not beneficial, which is in line with the recent study of a large sample of severe COVID-19 patients treated with lopinavir/ritonavir. 26 The children in our study did not receive steroids, as their respiratory status did not deteriorate sufficiently enough to merit this treatment. Abbreviations: AURTI, acute upper respiratory tract infection; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak

The global battle against SARS-CoV-2 and COVID-19

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Severe COVID-19 in children and young adults in the Washington, DC Metropolitan Region

COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features

An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19)

Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement

Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

First case of 2019 novel coronavirus infection in children in Shanghai

SARS-CoV-2 infection in children

A case report of neonatal COVID-19 infection in China

Coronavirus disease 2019 in children: surprising findings in the midst of a global pandemic

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Severe acute respiratory syndrome-related coronavirus: the species and its viruses-a statement of the Coronavirus Study Group

World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11

Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia

A novel coronavirus from patients with pneumonia in China

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Potential antiviral therapeutics for 2019 Novel Coronavirus

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Clinical characteristics of acute respiratory syndrome with SARS-CoV-2 infection in children in South China

of the three provinces in South China. The clinical characteristics were different from those of infected children and adults in Wuhan, Hubei. However, the number of cases in this study was relatively small and there were no severe or critical cases. The lack of representativeness is an obvious limitation.Our study suggested that children with SARS-CoV-2 infection may have mild fever and no obvious cough; however, the lymphocyte count is more frequently high than low and asymptomatic infection is more common. Antiviral therapy was not beneficial. The overall clinical manifestations were mild, with rare complications and good prognosis.Careful epidemiological investigations are essential for the early diagnosis of new coronavirus infection in children. The phenomenon of virus reactivation after discharge may be a cause for concern, and the contagiousness of asymptomatic infection needs further study.

The authors would like to express their gratitude to all hospitals 

The authors declare that there are no conflict of interests.

GZ, BW, and YG designed and wrote the paper. All authors conducted the clinical studies; WG, YW, and YG analyzed the data. All authors contributed to the study implementation, interpretation, and reporting. All authors have read and approved the manuscript.

http://orcid.org/0000-0002-4914-8124